Capital Asset Advisory Services LLC Acquires 2,070 Shares of Thermo Fisher Scientific Inc. $TMO

Capital Asset Advisory Services LLC raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 31.8% in the third quarter, HoldingsChannel reports. The firm owned 8,584 shares of the medical research company’s stock after buying an additional 2,070 shares during the quarter. Capital Asset Advisory Services LLC’s holdings in Thermo Fisher Scientific were worth $4,164,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. CBIZ Investment Advisory Services LLC lifted its stake in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after acquiring an additional 33 shares during the period. Anderson Financial Strategies LLC bought a new position in Thermo Fisher Scientific in the 1st quarter worth $30,000. Capital A Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 825.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after purchasing an additional 66 shares during the period. DiNuzzo Private Wealth Inc. boosted its position in Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 61 shares in the last quarter. Finally, HighMark Wealth Management LLC lifted its stake in shares of Thermo Fisher Scientific by 140.6% in the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 45 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on TMO shares. Hsbc Global Res upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a report on Monday, December 1st. TD Cowen increased their price target on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. UBS Group lifted their target price on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a report on Thursday, October 23rd. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $616.60.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $575.78 on Tuesday. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company has a market capitalization of $216.32 billion, a P/E ratio of 33.26, a price-to-earnings-growth ratio of 4.18 and a beta of 0.90. The firm has a 50 day moving average of $566.49 and a 200 day moving average of $493.42. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. During the same period last year, the business posted $5.28 EPS. The company’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 9.94%.

Thermo Fisher Scientific announced that its board has approved a share repurchase plan on Thursday, November 6th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 17,104 shares of the firm’s stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at $65,247,057.48. This trade represents a 13.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Lisa P. Britt sold 10,225 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the transaction, the vice president directly owned 14,145 shares of the company’s stock, valued at $8,085,564.90. The trade was a 41.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 149,271 shares of company stock worth $86,507,282. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.